Loading
Running an RNA-based fusion test across nearly 22,000 tumours of every kind found this rare but treatable fusion in about one in five hundred, most often in lung cancer, and with a different partner gene almost every time.
Tumour specimens submitted for molecular profiling that underwent fusion testing by anchored multiplex polymerase chain reaction for targeted RNA sequencing were retrospectively reviewed. Of 21,858 specimens profiled between September 2015 and December 2018, 41 cases, 0.2%, harboured an NRG1 fusion, with multiple distinct fusion partners. Fusions occurred across tumour types; the greatest number was in non-small-cell lung cancer, 25 cases, although this represented only 0.3% of the lung cancers tested. Gallbladder, renal cell, bladder, ovarian, pancreatic, breast, neuroendocrine, sarcoma and colorectal cases were also identified.
It put a number on how rare NRG1 fusions are and showed that heterogeneous partners make RNA-based testing the only reliable way to find them, which is the practical argument for adding a fusion panel to a driver-negative lung cancer work-up.
Shares NRG1 gene fusion, NRG1, Gene fusion, RNA sequencing & expression profiling.
Shares Gene fusion, RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares NRG1, Clinical Cancer Research, RNA sequencing & expression profiling, Receptor tyrosine kinase activation.
Shares NRG1 gene fusion, NRG1, Non-small-cell lung cancer.
Shares NRG1, Tumour-agnostic (tissue-agnostic) approval, Receptor tyrosine kinase activation, HER2.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling, Non-small-cell lung cancer.
Shares Clinical Cancer Research, Receptor tyrosine kinase activation, Comprehensive genomic profiling, HER2.
Shares NRG1 gene fusion, NRG1, Receptor tyrosine kinase activation, HER2.